Patents by Inventor Georg F. Weber
Georg F. Weber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11791043Abstract: A method is provided for prognosing a risk in a patient diagnosed with a premalignant lesion of the breast of the lesion progressing to breast cancer, the method comprising: providing a tissue sample of the premalignant lesion; detecting one or more variants of Osteopontin (OPN) selected from OPN-a, OPN-b and OPN-c in the sample; and prognosing an elevated risk of the lesion progressing to breast cancer if OPN-b and/or OPN-c is detected and/or OPN-a is elevated above normal levels in the tissue sample. Methods of assessing risk of death from breast cancer, methods of treatment, and kits for prognosis are also provided herein.Type: GrantFiled: September 6, 2018Date of Patent: October 17, 2023Assignee: University of CincinnatiInventor: Georg F. Weber
-
Publication number: 20230203193Abstract: This disclosure relates to isolated polypeptides with antigen specificity to OPN-c and to methods of their use for treating or determining or screening the presence of an invasive cancer. Included are three heavy chains CDRs and three light chain CDRs with binding specificity to OPN-c with little to no cross-reactivity to OPN-a and OPN-b. The ability to bind and detect OPN-c expression as well an OPN-c neutralization are also included.Type: ApplicationFiled: June 2, 2021Publication date: June 29, 2023Inventor: GEORG F. WEBER
-
Patent number: 10934591Abstract: The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3).Type: GrantFiled: December 13, 2017Date of Patent: March 2, 2021Assignees: VENTANA MEDICAL SYSTEMS, INC., UNIVERSITY OF CINCINNATIInventors: Mana Mirza, Elizabeth Shaughnessy, John K. Hurley, Kristie A. Vanpatten, Gary Pestano, Georg F. Weber
-
Publication number: 20200271652Abstract: A method is provided for prognosing a risk in a patient diagnosed with a premalignant lesion of the breast of the lesion progressing to breast cancer, the method comprising: providing a tissue sample of the premalignant lesion; detecting one or more variants of Osteopontin (OPN) selected from OPN-a, OPN-b and OPN-c in the sample; and prognosing an elevated risk of the lesion progressing to breast cancer if OPN-b and/or OPN-c is detected and/or OPN-a is elevated above normal levels in the tissue sample. Methods of assessing risk of death from breast cancer, methods of treatment, and kits for prognosis are also provided herein.Type: ApplicationFiled: September 6, 2018Publication date: August 27, 2020Inventor: Georg F. Weber
-
Publication number: 20180119232Abstract: The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3).Type: ApplicationFiled: December 13, 2017Publication date: May 3, 2018Inventors: Mana Mirza, Elizabeth Shaughnessy, John K. Hurley, Kristie A. Vanpatten, Gary Pestano, Georg F. Weber
-
Patent number: 9873915Abstract: The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3).Type: GrantFiled: October 16, 2008Date of Patent: January 23, 2018Assignees: Ventana Medical Systems, Inc., University of CincinnatiInventors: Mana Mirza, Elizabeth Shaughnessy, Georg F. Weber, John K. Hurley, Kristie A. Vanpatten, Gary Pestano
-
Patent number: 8969020Abstract: An isolated sequence SGSSEEKQNAVSSEET (OPNcPEP) SEQ ID NO: 8, and uses thereof. The peptide enhanced soft agar clone formation but did not support the growth of cells in plastic dishes, consistent with supporting anchorage-independence rather than growth. This sequence represented and is unique for a domain around the splice junction of OPN variant -c (OPN-c). OPN-c was expressed in a variety of tumor cell lines, but not in normal tissues (e.g., non-cancerous tissue) or in benign tumors. OPN-c antibody may be administered to a patient with a cancer associated with OPN-c expression to prevent the formation and growth of metastases. OPN-c may be used as a diagnostic to determine whether a patient has a malignant, rather than a benign, growth. OPN-c may be used to detect or identify agents that inhibit or mimic OPN-c expression or activity.Type: GrantFiled: August 10, 2010Date of Patent: March 3, 2015Assignee: MetaMol Theranostics LLCInventor: Georg F. Weber
-
Publication number: 20110033857Abstract: An isolated sequence SGSSEEKQNAVSSEET (OPNcPEP) SEQ ID NO: 8, and uses thereof. The peptide enhanced soft agar clone formation but did not support the growth of cells in plastic dishes, consistent with supporting anchorage-independence rather than growth. This sequence represented and is unique for a domain around the splice junction of OPN variant-c (OPN-c). OPN-c was expressed in a variety of tumor cell lines, but not in normal tissues (e.g., non-cancerous tissue) or in benign tumors. OPN-c antibody may be administered to a patient with a cancer associated with OPN-c expression to prevent the formation and growth of metastases. OPN-c may be used as a diagnostic to determine whether a patient has a malignant, rather than a benign, growth. OPN-c may be used to detect or identify agents that inhibit or mimic OPN-c expression or activity.Type: ApplicationFiled: August 10, 2010Publication date: February 10, 2011Applicant: METAMOL THERANOSTICS, LLCInventor: Georg F. Weber
-
Patent number: 7807790Abstract: An isolated sequence SGSSEEKQNAVSSEET (OPNcPEP) SEQ ID NO: 8, and uses thereof. The peptide enhanced soft agar clone formation but did not support the growth of cells in plastic dishes, consistent with supporting anchorage-independence rather than growth. This sequence represented and is unique for a domain around the splice junction of OPN variant-c (OPN-c). OPN-c was expressed in a variety of tumor cell lines, but not in normal tissues (e.g., non-cancerous tissue) or in benign tumors. OPN-c antibody may be administered to a patient with a cancer associated with OPN-c expression to prevent the formation and growth of metastases. OPN-c may be used as a diagnostic to determine whether a patient has a malignant, rather than a benign, growth. OPN-c may be used to detect or identify agents that inhibit or mimic OPN-c expression or activity.Type: GrantFiled: November 14, 2006Date of Patent: October 5, 2010Assignee: MetaMol Theranostics, LLCInventor: Georg F. Weber
-
Publication number: 20100209928Abstract: The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3).Type: ApplicationFiled: October 16, 2008Publication date: August 19, 2010Inventors: Mana Mirza, Elizabeth Shaughnessy, Georg F. Weber, John K. Hurley, Kristie A. Vanpatten, Gary Pestano
-
Publication number: 20090061436Abstract: An isolated sequence SGSSEEKQNAVSSEET (OPNcPEP) SEQ ID NO: 8, and uses thereof. The peptide enhanced soft agar clone formation but did not support the growth of cells in plastic dishes, consistent with supporting anchorage-independence rather than growth. This sequence represented and is unique for a domain around the splice junction of OPN variant -c (OPN-c). OPN-c was expressed in a variety of tumor cell lines, but not in normal tissues (e.g., non-cancerous tissue) or in benign tumors. OPN-c antibody may be administered to a patient with a cancer associated with OPN-c expression to prevent the formation and growth of metastases. OPN-c may be used as a diagnostic to determine whether a patient has a malignant, rather than a benign, growth. OPN-c may be used to detect or identify agents that inhibit or mimic OPN-c expression or activity.Type: ApplicationFiled: November 14, 2006Publication date: March 5, 2009Inventor: Georg F. Weber
-
Patent number: 7160986Abstract: The present invention relates to BCL-x?, a novel isoform of the BCL-x family of proteins which is predominantly expressed in T-lymphocytes and is associated with resistance to apoptosis. Both compositions of matter and methods are described which are useful in the treatment or prevention of immune system disorders.Type: GrantFiled: July 29, 2002Date of Patent: January 9, 2007Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Xiao-Feng Yang, Georg F. Weber, Harvey Cantor
-
Publication number: 20040180343Abstract: The methods and compositions of the invention provide means of detecting nucleic acids. The methods employ hybridization of test nucleic acids to nucleic acid probes or analogs thereof (e.g., peptide nucleic acid probes).Type: ApplicationFiled: March 12, 2003Publication date: September 16, 2004Inventor: Georg F. Weber
-
Publication number: 20040142865Abstract: The invention relates to therapies for treating cancer patients by targeting the osteopontin isoforms OPN-b and OPN-c. Osteopontin is a cytokine that is essential for cellular immunity, particularly through its full length form, OPN-a. OPN-b and OPN-c are splice variants that lack exons 5 and 4, respectively, of the protein's six translated exons. The invention provides methods for treating cancer patients with therapeutics that inhibit or degrade the OPN-b or OPN-c isoforms specifically, thereby leaving the innocuous OPN-a form intact and available to perform its normal functions in the cell.Type: ApplicationFiled: October 2, 2003Publication date: July 22, 2004Inventor: Georg F. Weber
-
Publication number: 20030013171Abstract: The present invention relates to BCL-x&ggr;, a novel isoform of the BCL-x family of proteins which is predominantly expressed in T-lymphocytes and is associated with resistance to apoptosis. Both compositions of matter and methods are described which are useful in the treatment or prevention of immune system disorders.Type: ApplicationFiled: July 29, 2002Publication date: January 16, 2003Applicant: Dana-Farber Cancer InstituteInventors: Xiao-Feng Yang, Georg F. Weber, Harvey Cantor
-
Patent number: 6472170Abstract: The present invention relates to BCL-x&ggr;, a novel isoform of the BCL-x family of proteins which is predominantly expressed in T-lymphocytes and is associated with resistance to apoptosis. Both compositions of matter and methods are described which are useful in the treatment or prevention of immune system disorders.Type: GrantFiled: July 23, 1997Date of Patent: October 29, 2002Assignee: Dana-Farber Cancer InstituteInventors: Xiao-Feng Yang, Georg F. Weber, Harvey Cantor